Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dengvaxia US Pregnancy Registry
Sponsor: Sanofi Pasteur, a Sanofi Company
Summary
The primary objective of this study is to assess maternal, obstetrical, pregnancy, and neonatal and infant outcomes among women and their offspring(s) vaccinated with Dengvaxia during their pregnancy
Official title: Dengvaxia US Pregnancy Registry: A Surveillance Study to Assess the Safety of Dengvaxia Among Exposed Pregnant Women and Their Offsprings (DNG00044)
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
500
Start Date
2023-01-01
Completion Date
2029-06-30
Last Updated
2026-01-21
Healthy Volunteers
Yes
Conditions
Interventions
Dengue Tetravalent Vaccine, Live
Pharmaceutical form: Powder and solvent for suspension for injection Route of administration: Subcutaneous
Locations (1)
Investigational Site
San Juan, Puerto Rico